BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/24/2025 9:11:07 AM | Browse: 1 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 113810
Country France
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Multibipolar radiofrequency vs single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Cécilia Bahloul, Agnès Rode, Pierre Pradat, Laurent Milot, Jérôme Dumortier, Philippe Merle, Jean-Yves Mabrut, Loïc Boussel and Angelo Della Corte
Funding Agency and Grant Number
Corresponding Author Angelo Della Corte, Department of Radiology, Hospices Civils de Lyon, 103 Gd Rue de la Croix-Rousse, Lyon 69002, Auvergne-Rhône-Alpes, France. a.dellacortetartaglione@gmail.com
Key Words Local tumor progression; Ablation; Microwave; Radiofrequency; Hepatocellular carcinoma
Core Tip There is limited data comparing multibipolar radiofrequency ablation (mbp-RFA) and microwave ablation (MWA) for treating hepatocellular carcinoma (HCC). This study analyzed 362 patients with newly diagnosed HCC who underwent either mbp-RFA (242 patients, 323 tumors) or MWA (120 patients, 168 tumors). Results showed that mbp-RFA provided better local tumor control, with a lower local tumor progression rate (11.4% vs 25.2%) and a higher complete ablation rate (94.1% vs 87.5%) compared to MWA. The advantage of mbp-RFA was particularly significant for tumors larger than 3 cm, where MWA had a local tumor progression rate of 60.9% vs 21.6% with mbp-RFA. Despite these differences in efficacy, both techniques had similar major complication rates (9.5% vs 7.5%). These findings suggest that mbp-RFA is a more effective option for larger, treatment-naïve HCC tumors while maintaining a comparable safety profile.
Citation Bahloul C, Rode A, Pradat P, Milot L, Dumortier J, Merle P, Mabrut JY, Boussel L, Della Corte A. Multibipolar radiofrequency vs single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma. World J Gastroenterol 2025; In press
Received
2025-09-04 06:26
Peer-Review Started
2025-09-04 06:26
To Make the First Decision
Return for Revision
2025-09-17 09:29
Revised
2025-10-01 07:00
Second Decision
2025-11-24 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-11-24 09:11
Articles in Press
2025-11-24 09:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com